Information on the person treated (e.g. sociodemographic data), on the treating physician, and on the treatment – i.e. the date of prescription, previous treatment with medicinal cannabis products and its duration, indications (including primary and relevant secondary diagnoses), medicinal cannabis product (product name, dosage form, total THC and CBD content, dosage), symptom-relevant concomitant medication (product, dosage), effects, adverse effects and treatment-related changes in symptoms.
To allow treatment outcomes to be monitored, data is to be collected several times – at the time of first prescription (baseline data collection), after one year and after two years of treatment, or earlier, if treatment is terminated before the end of the first or second year. Based on this data, prescription practices are to be tracked and the treatment effects observed in various indications are to be documented. This will facilitate the evaluation of the revised Act and serve as a guide for the cantonal enforcement authorities and physicians providing treatment. In addition, the data collected should also provide a basis for further clinical research.